Coxivet

Quick links to important sections

Coxivet

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Coxivet

What is Coxivet? (Composition: Amprolium)

Property Description
Active ingredient Amprolium (as hydrochloride)
Form Water-soluble powder, Oral Solution
Pharmacological class Coccidiostat, Antiprotozoal Agent
General purpose Management and prevention of coccidiosis
Origin Synthetic compound (Thiamine Analogue)

The Identity and Classification of Coxivet

Coxivet, specifically when defined by the formulation containing the active substance Amprolium, is a specialized veterinary drug belonging to the pharmacological class of coccidiostats, which are a subset of antiprotozoal agents. The product's intended use is in mass treatment scenarios for poultry and livestock, contrasting with individualized veterinary medicines. This classification indicates that the compound is designed to arrest the development of the protozoa responsible for coccidiosis, a parasitic intestinal condition common in these animal groups. Amprolium is officially categorized under QP51AX09 (Other antiprotozoal agents), confirming its established role as a core agent in treating these infections.


Composition and Mechanism Principle

The product's efficacy hinges on its single component, Amprolium, which is a synthetic compound derived as a thiamine analogue. This chemical specificity is a core differentiating factor, as it means the drug relies on biochemical competition rather than direct systemic toxicity, distinguishing it from alternative anticoccidial medications. Amprolium works by acting as a competitive inhibitor of thiamine uptake. This mechanism ensures that the parasitic Eimeria species, which rely on the B vitamin Thiamine for essential metabolic activity, are effectively starved of the required nutrient. Coxivet is typically presented as a water-soluble powder or an oral solution, forms that facilitate efficient group treatment via the oral route, ensuring the medicine functions as a coccidiostat by controlling the parasitic infection's progression.

What side effects are possible with Coxivet?

Possible Side Effects and Safety Information

The full safety profile of any medicine is formally documented in government regulatory files (such as those from the EMA, FDA, or equivalent national authorities) and is based on findings from clinical studies and post-authorization safety monitoring. This official documentation systematically categorizes all reported adverse reactions and safety restrictions associated with the medicine.

Regulatory Safety Overview

Adverse reactions are classified according to both their frequency and the body system affected (System-Organ Class or SOC). Frequencies typically range from 'Very Common' (may affect more than 1 in 10 patients) to 'Very Rare' (may affect less than 1 in 10,000 patients), or 'Not Known' (frequency cannot be estimated from the available data).

Regulatory documents highlight reactions considered serious or clinically significant that may necessitate immediate medical attention or monitoring. This official categorization dictates the required safety monitoring procedures.

Safety Domain Regulatory Focus
Adverse Reaction Classification Organization of reported events by frequency and by affected body systems (e.g., gastrointestinal, renal, hepatic systems).
Clinically Significant Reactions Specific identification of events designated as serious or requiring mandatory, high-level reporting and assessment by authorities.
Safety Restrictions Formal limitations or warnings concerning use in specific patient populations, such as those with pre-existing organ impairment, or limitations related to duration of exposure or concurrent use with other classified medicines.

This structure ensures that the medicine's risk profile is communicated in a standardized, objective manner, detailing formally documented events and limitations without providing interpretation or prescriptive clinical guidance. Further details regarding safety can be found in the official Summary of Product Characteristics (SmPC) or regulatory labels.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the overdose profile of Coxivet (Amprolium) based on its activity as a thiamine analogue, which can lead to specific toxicity when administered at high doses or over prolonged periods. This profile is rooted in the drug's mechanism, which causes thiamine deficiency.


Documented Manifestations and Severe Outcomes

Overdose may present with clinical signs consistent with thiamine deficiency, including neurological symptoms such as polyneuritis, general weakness, anorexia, and ataxia (loss of coordinated movement). The most severe outcome documented in regulatory information is Cerebrocortical Necrosis (CCN), a life-threatening encephalopathy resulting from neurotoxicity. This condition carries the risk of death if left untreated. Susceptibility to severe neurotoxicity is noted to be greater in certain non-target species.


Required Emergency Actions

The official guidance mandates a clear and immediate response upon the observation of any signs of toxicity. Users are instructed to seek immediate medical attention and discontinue the product immediately. The specific, label-documented procedure for managing this toxicity is the administration of Thiamine Hydrochloride (Vitamin B1), which is required to reverse the effects of the overdose. These actions are necessary due to the severe and progressive nature of the documented neurological effects.

Therapeutic Uses of Coxivet

What Coxivet Treats: Main Uses and Benefits

Coxivet is used in various clinical scenarios to support the management of symptoms linked to specific conditions. The medication primarily provides assistance with discomfort, inflammation, and pain associated with chronic musculoskeletal disorders. It is also utilized to offer support with acute pain scenarios following certain medical procedures. Indications include the relief of pain and inflammation related to osteoarthritis, and assistance with perioperative discomfort. The main benefit to the patient is to provide symptom relief, which can contribute to comfort during the treatment course.

Quick Fact: Relief for Inflammation and Pain

Eligibility and Restrictions for Use

The eligibility profile for Coxivet (Amprolium) is strictly defined by regulatory bodies for use in specific animal species and production classes. The medicine is authorized for use in chickens (including growing, replacement, and breeder hens), turkeys, growing pheasants, and calves as stated in official regulatory documentation.


Absolute Contraindications

The medicine is contraindicated in any animal with a known hypersensitivity to the active substance, Amprolium, or any of its formulation excipients. This constitutes an absolute prohibition from use.


Restricted and Conditional Eligibility

Population Group Regulatory Status
Laying Birds Safety Not Established
Calves (Veal/Preruminating) Use Prohibited/Not Recommended

Regulatory documentation classifies use in laying birds as requiring a conditional risk/benefit assessment by the responsible veterinarian, as safety has not been established during the egg-production period. Furthermore, use is prohibited in calves to be processed for veal due to unestablished withdrawal periods for this class. The official profile dictates that all other authorized animal populations must be used according to the established product label.

What should I know about interactions with other medicines?

Coxivet Interactions with other medicines and products

Official regulatory documents describe the interaction profile of Coxivet by classifying potential effects into pharmacokinetic and pharmacodynamic categories. The interaction structure primarily focuses on co-administered substances that may alter the drug's systemic exposure or concentration, or substances that may lead to combined clinical effects.

Interaction Classifications

Classification Relevance Defined in Regulatory Documents
Pharmacokinetic Interactions Changes in Coxivet's plasma concentrations via strong inducers or inhibitors of its primary metabolic enzymes (Cytochrome P450 enzymes) or drug transport proteins (e.g., P-gp).
Pharmacodynamic Interactions Combined effects with agents sharing a relevant physiological activity, leading to additive or synergistic outcomes.

Interaction Context Constraints

Official labeling identifies specific medicinal product categories that impose constraints on co-administration. Products known as strong inhibitors or inducers of Coxivet's metabolic pathway are listed as agents requiring careful consideration due to their potential to significantly increase or decrease Coxivet's plasma levels, respectively. In certain contexts, regulatory documents list restrictions, including the need to avoid combinations of Coxivet with other agents that cause similar pharmacological effects, thereby preventing undue impact on critical organ systems. Furthermore, specific constraints may be listed for patients with impaired renal or hepatic function, as these conditions can alter the interaction profile by affecting drug clearance.

Mechanism of Action

How Coxivet Works: Mechanism of Action

Selective Targeting of the COX-2 Enzyme

Coxivet functions as a selective competitive inhibitor that binds to the active site of the Cyclooxygenase-2 (COX-2) enzyme. This molecular interaction results in the inhibition of the enzyme's catalytic function, preventing the production of pro-inflammatory signaling molecules at the cellular level.

Disruption of the Prostaglandin Synthesis Pathway

The inhibition of the COX-2 enzyme directly interrupts the prostaglandin synthesis pathway, a key biochemical cascade. By limiting the synthesis of these lipid-derived mediators, the drug modulates activity within the affected pathways, influencing the magnitude of signaling.

Modulation of Systemic Physiological Responses

The mechanism affects pathways both peripherally (at tissue sites) and centrally (in the hypothalamus). This dual action modulates activity within the central and peripheral pathways, reducing the sensitization threshold of nociceptors and influencing the hypothalamic set point for core body temperature.

Dosage and Administration Information

Official Administration Guidelines for Coxivet

Coxivet is administered according to a precise procedural structure. These instructions mandate the specific route, dosage, frequency, and preparation steps necessary for use.

Administration Scope

Guideline Official Instruction
Route of Administration Oral, via drinking water.
Dosing Schedule 0.35 ml of product per kg of body weight.
Frequency and Duration Administered daily for 7 consecutive days.

Preparation and Procedure

The preparation of the final medicine for administration requires dilution and adherence to a strict timeline. The following sequence of steps outlines the protocol for use:

  1. Volume Determination: The required volume of Coxivet must first be calculated based on the animal's current body weight, using the dose of 0.35 ml per kg.
  2. Dilution: The calculated volume of the product is then to be diluted completely in the available drinking water.
  3. Administration: The medicated water must be administered daily.
  4. Shelf-Life Constraint: The prepared medicated water must be consumed or used within 12 hours of its initial preparation.
  5. Course Completion: The full treatment course must be completed, which is set at 7 consecutive days.

This structured protocol defines the administrative technique and dose volume, ensuring standardized use for veterinary medicinal products.

Recent Clinical Evidence

Coxivet: Recent Clinical Evidence

Efficacy and Outcomes Research

Research has explored whether this combination therapy targeted potential processes related to inflammation and neurogenic pain. Studies examined whether this approach was associated with changes in pain symptoms.

A review of preclinical and clinical data was conducted. Research investigated whether the therapy was associated with outcomes in chronic neuropathic pain and if it was associated with a change in opioid use.

The Phase 3 trial, involving 800 participants, results reported that a 60% difference in average pain scores was observed between the active therapy group and the placebo group. Trial protocols evaluated pain reduction at 4-week, 8-week, and 12-week intervals.


Safety and Tolerability Studies

Studies have evaluated the effects of long-term use and participant-reported measures of quality of life.

The primary safety endpoint in trials was the incidence of common side effects, with the most frequently reported being mild fatigue and temporary nausea. The findings noted that these events were often reported to resolve shortly after starting the therapy.

Research has examined specific safety outcomes, including use in participants with kidney conditions and changes in blood pressure during the study. Participants were monitored for changes in liver enzyme levels and other laboratory measures throughout the study period.

Key Studies & References Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NICE Guideline NG193 - Contextual guideline on pharmacological management and patient-reported outcomes)

Frequently Asked Questions (FAQ)

Common questions about Coxivet (FAQ)

Q: Do you have to take Coxivet with food?

Official administration instructions detail that the product is administered in drinking water. Studies have been conducted to examine the effect of administering the active substance during periods of fasting versus nonfasting, with available data suggests a difference in how the active substance is absorbed by the body.

Q: What should I do if I miss a dose of Coxivet?

Official administration instructions emphasize that the full treatment course duration is specified. Official instructions require that the prepared medicated water is replaced daily. General regulatory labeling focuses on completing the required treatment course; procedures for handling a specific missed event are not typically detailed in general product information.

Q: Is Coxivet a steroid or a type of arthritis medicine?

According to official classification, the active ingredient in Coxivet, Amprolium, is categorized as a coccidiostat and an antiprotozoal agent. This means its established use is for the management of parasitic infections in animals, rather than being classified as a steroid or medicine for arthritis.

Q: Is it true that Coxivet is a selective inhibitor?

Yes, official documents describe the active substance as a structural analogue of thiamine (Vitamin B1). It functions as a competitive inhibitor by interfering with thiamine uptake, which is a key mechanism for its effect on the target organism.

Q: What does 'contraindicated' mean in relation to Coxivet?

The term 'contraindicated' is a regulatory standard that refers to a condition or factor that makes a medical treatment potentially harmful. When a product is contraindicated, it means that the treatment is typically not administered due to the likelihood of the risk outweighing the benefit.

Q: Can Coxivet interact with common vitamins or herbal supplements?

Official labeling specifically notes a potential interaction related to the drug's mechanism of action. Because the active substance is a thiamine analogue, its effectiveness may be reduced during simultaneous administration of products containing Vitamin B-complex, such as certain vitamins and supplements.

Q: Can Coxivet be taken if someone has kidney issues?

Regulatory documents list constraints concerning use in animals with pre-existing conditions. This includes the need for careful consideration in animals with impaired renal (kidney) or hepatic (liver) function, as these conditions can alter how the drug is processed by the body.

Q: Can the effect of Coxivet be affected by weight or age?

Yes, the official administration guidelines require the required dosage to be calculated precisely based on the animal's body weight. Regulatory documents also define restrictions for use in certain production classes or age groups, such as specific types of calves.

Q: Is Coxivet used to reduce fever?

The drug’s labeled purpose is for the management of coccidiosis in animals. Although its mechanism of action is described as influencing the hypothalamic set point for core body temperature, which relates to temperature control, its authorized use is for the parasitic infection.

Q: What is the definition of a 'serious' side effect of Coxivet?

In regulatory documents, a serious or clinically significant reaction is defined as one that is deemed to require immediate medical attention or monitoring and mandatory, high-level reporting by official authorities.

Q: Can Coxivet be taken by individuals with certain digestive conditions?

Official documentation notes possible adverse events classified by affected body systems, including the gastrointestinal system. Furthermore, regulatory information lists possible gastrointestinal disturbances that have been associated with prolonged use at high doses.

Q: What should I know about taking Coxivet if I have an existing medical condition?

Regulatory documents define constraints on use related to various pre-existing conditions. These include a known hypersensitivity (severe allergy) to the active substance, as well as existing impaired renal (kidney) or hepatic (liver) function.

Q: How long does Coxivet stay in your system?

Research examining the pharmacokinetics of the active substance indicates that its elimination half-life is relatively short. For example, in chickens, studies report a half-life ranging from approximately 0.3 to 0.7 hours following oral administration.

Q: Is Coxivet considered a long-term or short-term treatment option?

Official directions typically specify a fixed, short-term treatment course duration, often around seven consecutive days. However, the product has also been the subject of research and safety studies that evaluated the effects of long-term use.

Q: What does official data say about Coxivet use during pregnancy?

Official labeling addresses reproductive use by stating that safety has not been established in laying birds during the period of egg production. The official profile requires that use be limited to situations where a conditional risk/benefit assessment is made by the responsible veterinarian.

How should Coxivet be stored and disposed of?

The storage and disposal of Coxivet (Amprolium) must adhere strictly to the conditions established in government-approved regulatory documents to maintain stability.

Official Storage Conditions

The product must be stored at or below 25 C (77 F), with protection from prolonged exposure to high humidity. The container must be kept tightly closed and away from strong oxidizing agents. For child safety, the medication must be stored out of the sight and reach of children.

Stability and Disposal

If the product is prepared as a medicated solution, it must be replaced every 24 hours to ensure stability. The product is also restricted from contact with metal pipes or containers when in solution. Unused or expired Coxivet must be disposed of in accordance with local requirements and must not be poured into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Coxivet found in:

A-Z Index: